Prevalence of chronic fatigue syndrome in a community population in Japan.
Kawakami, N, Iwata, N, Fujihara, S et al. · The Tohoku journal of experimental medicine · 1998 · DOI
Quick Summary
This Japanese study looked at how common ME/CFS is in everyday communities by interviewing 137 people. Researchers found that about 1 in 67 people had severe, persistent fatigue that met ME/CFS criteria and significantly disrupted their daily life. The findings suggested ME/CFS might be more common in Japan than in Western countries studied previously.
Why It Matters
This study provides rare international prevalence data for ME/CFS outside Western populations, highlighting that the disease occurs globally and may manifest differently across cultures. Understanding cross-cultural differences in disease prevalence and presentation is crucial for developing culturally-informed diagnostic approaches and ensuring ME/CFS is recognized in diverse populations.
Observed Findings
Point prevalence of ME/CFS: 1.5% (95% CI 0.4-5.2%)
Nine-month prevalence of ME/CFS: 1.5% (95% CI 0.4-5.2%)
2 out of 137 respondents met both 1994 CDC and British diagnostic criteria
0 out of 137 respondents met 1989 CDC criteria for CFS
Both cases experienced ≥50% reduction in daily activity due to fatigue with no alternative diagnoses
Inferred Conclusions
ME/CFS prevalence in Japan (1.5%) appears higher than previously reported Western prevalence rates
Differences in diagnostic criteria significantly impact case identification and prevalence estimates
Cross-cultural variation in ME/CFS definition, prevalence, or symptomatology may exist and warrants further investigation
Remaining Questions
Why did the same cases fulfill 1994 CDC and British criteria but not 1989 CDC criteria, and what do these differences mean?
Does the higher Japanese prevalence reflect true epidemiological differences, or differences in symptom expression, healthcare access, and case identification?
How do cultural factors, healthcare systems, and symptom attribution affect ME/CFS diagnosis and prevalence estimation across different populations?
What This Study Does Not Prove
This study does not establish causation for ME/CFS or identify why prevalence might differ between Japan and Western countries. The small sample size (n=137) and single-site Japanese sample limit generalizability, and the study cannot distinguish between true epidemiological differences versus differences in diagnostic criteria application, healthcare-seeking behavior, or symptom interpretation across cultures.
Tags
Symptom:Fatigue
Method Flag:Weak Case DefinitionNo ControlsSmall Sample